Abstract
Human immunodeficiency virus (HIV) co-infection accelerates both hepatitis C (HCV) and hepatitis B (HBV) natural history leading to faster progression to and increased incidence of cirrhosis, hepatocellular carcinoma (HCC) and death. HIV/HCV co-infected patients have twice the risk of developing cirrhosis and a sixfold increased risk of liver failure compared with those with HCV alone. Effective treatment of HBV and HCV in HIV co-infected patients increases survival. Treatment responses to TVR do not differ between HIV/HCV co-infected and HCV mono-infected patients. In patients treated with TVR combination treatment, overall safety and tolerability profile was comparable to that previously observed in chronic genotype 1 HCV mono-infected patients. In HIV/HBV co-infected patients, any treatment decision for hepatitis B should take into account the possible impact on HIV and vice-versa. For HIV/HBV co-infected patients, initiation of ART with active anti-HBV coverage is now recommended at any CD4+T-cell count to reduce the risk of liver disease progression.
| Original language | English |
|---|---|
| Title of host publication | Mount Sinai Expert Guides |
| Subtitle of host publication | Hepatology |
| Publisher | wiley |
| Pages | 78-95 |
| Number of pages | 18 |
| ISBN (Electronic) | 9781118748626 |
| ISBN (Print) | 9781118517345 |
| DOIs | |
| State | Published - 1 Jan 2014 |
Keywords
- boceprevir
- entecavir
- human immunodeficiency virus /hepatitis B co-infection
- human immunodeficiency virus /hepatitis C co-infection
- lamivudine
- pegylated interferon
- ribavirin
- sustained virologic response
- telaprevir
- tenofovir
Fingerprint
Dive into the research topics of 'HIV/HCV and HIV/HBV Co-infections'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver